Biote Corp. Reports Q3 2025 Financial Results

Biote Corp. ( (BTMD) ) has released its Q3 earnings. Here is a breakdown of the information Biote Corp. presented to its investors.

Biote Corp., a company specializing in hormone optimization and healthy aging solutions, is a prominent player in the healthcare sector, focusing on enhancing the healthspan of patients through innovative approaches. In its latest earnings report for the third quarter of 2025, Biote Corp. reported a revenue of $48.0 million, with a gross profit margin of 71.8%. The company also highlighted its strategic priorities, including accelerating growth from new providers and maximizing value from top-tier clinics.

The financial performance for the third quarter showed a decrease in total revenue by 6.7% compared to the previous year, primarily due to a 10.4% decline in procedure revenue, which was partially offset by an 8.4% growth in dietary supplements revenue. Despite these challenges, Biote achieved a net income of $9.2 million, with diluted earnings per share of $0.22. The company also reported an adjusted EBITDA of $12.9 million, reflecting a 20.5% decrease from the prior-year quarter.

Biote’s management reiterated their confidence in the company’s strategic direction, emphasizing the progress made in organizational restructuring and the strengthening of practitioner relationships. The company also repurchased approximately one million shares of Class A common stock, demonstrating its commitment to building long-term shareholder value. Looking ahead, Biote maintains its 2025 financial outlook, forecasting revenue above $190 million and adjusted EBITDA above $50 million.

In conclusion, Biote Corp. remains focused on driving sustainable growth and enhancing shareholder value through its strategic initiatives. The company is well-positioned to capitalize on the underserved market for hormone optimization and therapeutic wellness, with a strong emphasis on advancing patient healthspan and restoring vitality.